Insilico launches AI Longevity Vaccines research for age-related disease

Insilico Medicine said it launched Longevity Vaccines, a research initiative that uses generative AI and programmable RNA medicine to design single-administration, self-limiting in vivo cell therapies meant to eliminate early cellular drivers of age-related disease.

Same-day HEALTH primary that an AI drug-discovery company is launching a preventive cell-therapy research program aimed at aging biology — a discrete initiative with a named platform and a first focus on immune-system rejuvenation. This is a research launch, not a proven patient result.

Goal, still company — research aim, not a proven outcome: develop programmable, self-limiting preventive treatments that eliminate early cellular drivers of age-related disease. Programmable here means the same delivery shell can be retargeted at different cell types. Self-limiting means the instruction is meant to fade, not stay on forever. File that job as Insilico’s stated aim. This desk is not treating it as a completed clinical result.

Approach, company: the program uses generative AI — software that designs new molecules and genetic constructs — and programmable RNA medicine to design single-administration, self-limiting in vivo cell therapies. In vivo means the work happens inside the patient’s body, not in a dish and not as a separately manufactured cell product. File that approach as Insilico’s. This desk did not design a construct.

Targets, still company: the approach is powered by Pharma.AI and aging foundation models. It is aimed at senescent, fibrotic, and autoreactive cells, starting with immune-system rejuvenation. Senescent cells are worn-out cells that can keep sending inflammation signals. Fibrotic cells help scar tissue build up. Autoreactive cells are immune cells that attack the body’s own tissue. File those target classes and that first focus as Insilico’s.

Delivery chassis, company: a short-lived genetic instruction encoded in circular mRNA, or cmRNA, and packaged in a targeted lipid nanoparticle, or LNP. Inside the body, the company says, that package is meant to arm a patient’s own T cells — the immune cells that can kill marked targets — to recognize and remove specific cell populations. Circular mRNA is a loop of messenger-RNA instructions that lasts longer than ordinary linear mRNA but is still meant to shut off. An LNP is a fat-based delivery shell. File that chassis as Insilico’s design description. This desk did not infuse a patient.

Antigen and target selection, still company: the Pharma.AI stack named on the page includes PandaOmics for multi-omics target discovery, generative biologics for new binder design, Chemistry42 for lipids and delivery chemistry, and inClinico for AI-assisted trial design, plus aging foundation models and Virtual Aging Cell. An antigen here is a surface marker the T cells would be taught to recognize. File those tool names as Insilico’s. How the stack is wired stays in Sources.

Strategy shift, company: Longevity Vaccines expands Insilico’s dual-purpose, aging-oriented discovery strategy from small-molecule drugs into RNA-encoded in vivo cell engineering. Dual-purpose, as the company uses it, means a program meant to hit both a named disease and a deeper aging process. File that expansion as Insilico’s. This desk is not inventing a new approved drug class.

First indication focus, still company: rejuvenation of the aging immune system — immunosenescence, meaning the immune system wearing down with age — by targeting senescent lymphocytes. Additional indications under evaluation, the company says, include metabolic dysfunction and membranous nephropathy, a kidney disease driven by the immune system attacking a kidney filter. File that first focus and those extra indications as Insilico’s evaluation list. This desk is not inventing trial enrollment or a start date.

Prior-program context, company — not the new product: Insilico cites Rentosertib (ISM001-055), an AI-designed small molecule now in Phase III for idiopathic pulmonary fibrosis, or IPF, a scarring lung disease, as the foundation for that dual-purpose strategy. File Rentosertib’s Phase III IPF status as Insilico’s. This desk is not treating Rentosertib as Longevity Vaccines, and it is not inventing an FDA clearance for the new initiative.

Optional company finance color, one line only: Insilico also printed first-half 2026 revenue of about $106 million on the same page. File that figure as Insilico’s. This filing is the research initiative, not an earnings card.

Plain English for the rest of the card: generative AI = software that designs new molecules or genetic constructs. Senescent cells = worn-out cells that can drive inflammation. cmRNA = circular messenger RNA, a loop of genetic instructions. LNP = lipid nanoparticle, a fat-based delivery shell. Immunosenescence = aging of the immune system. In vivo = inside the body. T cells = immune cells that can kill marked targets. Antigen = a surface marker those T cells would be taught to recognize. IPF = idiopathic pulmonary fibrosis, a scarring lung disease.

PRIMARY here: Insilico Medicine’s 15 Sep 2026 company newsroom — Tier A PRIMARY company source, the original record. News Medical’s same-day carry is a syndicate of that same originating text, not a second newsroom. The Longevity Vaccines launch, the programmable / self-limiting preventive aim, the generative-AI plus RNA approach, the senescent / fibrotic / autoreactive target classes, the immune-rejuvenation first focus, the cmRNA-in-LNP chassis, the Pharma.AI / PandaOmics / Chemistry42 / inClinico / Virtual Aging Cell stack, the dual-purpose expansion from small molecules, the metabolic-dysfunction and membranous-nephropathy evaluation list, the Rentosertib Phase III IPF context, and the about-$106-million first-half 2026 revenue line are company-attributed. Clinical-outcome and platform claims stay company-stated — not independently verified here. NOT claimed: FDA clearance for Longevity Vaccines, clinical-trial enrollment for this initiative, a named trial partner for this program, a cure, independently verified patient outcomes, that this desk reviewed a protocol or visited a lab, a stock tip, or investment advice. Distinct from the already-filed openevidence-penn-medicine, sonus-medtronic-maternal-ultrasound-ai, microstructure-imaging-micsi-pet-fda, powerful-medical-queen-of-hearts-fda-de-novo, kairon-health-5m, knowtex-frontier-ai-lab, unc-openai-foundation-40m-cancer-vaccines, evvy-40m-series-b, azmed-azchest-fda-6th, and nvidia-chop-cardiac-monai.